Frankfurt - Delayed Quote EUR

Biofrontera AG N (B8FK.F)

Compare
2.2050
0.0000
(0.00%)
At close: January 10 at 8:14:03 AM GMT+1
Loading Chart for B8FK.F
DELL
  • Previous Close 2.2050
  • Open 2.2050
  • Bid 2.1050 x --
  • Ask 2.4350 x --
  • Day's Range 2.2050 - 2.2050
  • 52 Week Range 2.0250 - 10.6260
  • Volume 628
  • Avg. Volume 214
  • Market Cap (intraday) 13.794M
  • Beta (5Y Monthly) 0.41
  • PE Ratio (TTM) 2.66
  • EPS (TTM) 0.8300
  • Earnings Date Nov 29, 2024
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est --

Biofrontera AG, a biopharmaceutical company, engages in the research, development, and distribution of dermatological products in Germany, Spain, the United Kingdom, rest of Europe, the United States, and internationally. The company offers Ameluz and BF-RhodoLED lamp for the treatment of mild and moderate actinic keratoses on the face and scalp, field cancerization, and fatal squamous cell carcinoma. It also provides RhodoLED XL lamp for the treatment of multiple interspersed lesions; and Belixos, a cosmetic product for irritated and sensitive skin. The company has a license and supply agreement with Maruho Co., Ltd. Biofrontera AG was founded in 1997 and is headquartered in Leverkusen, Germany.

www.biofrontera.com

79

Full Time Employees

December 31

Fiscal Year Ends

Recent News: B8FK.F

View More

Performance Overview: B8FK.F

Trailing total returns as of 1/10/2025, which may include dividends or other distributions. Benchmark is

.

YTD Return

B8FK.F
5.50%
DAX P
1.54%

1-Year Return

B8FK.F
80.91%
DAX P
21.13%

3-Year Return

B8FK.F
92.81%
DAX P
26.76%

5-Year Return

B8FK.F
97.70%
DAX P
49.79%

Compare To: B8FK.F

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: B8FK.F

View More

Valuation Measures

Annual
As of 1/10/2025
  • Market Cap

    13.79M

  • Enterprise Value

    11.18M

  • Trailing P/E

    2.67

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    0.74

  • Price/Book (mrq)

    0.79

  • Enterprise Value/Revenue

    0.62

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -11.85%

  • Return on Assets (ttm)

    -6.84%

  • Return on Equity (ttm)

    -14.71%

  • Revenue (ttm)

    21.67M

  • Net Income Avi to Common (ttm)

    -2.57M

  • Diluted EPS (ttm)

    0.8300

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    2.21M

  • Total Debt/Equity (mrq)

    5.19%

  • Levered Free Cash Flow (ttm)

    -4.29M

Research Analysis: B8FK.F

View More

Company Insights: B8FK.F

Research Reports: B8FK.F

View More